• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Adex Liqui-Gels 200
    / Dexcel


    Active Ingredient
    Ibuprofen 200 mg

    Status in Israel
    OTC

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft

    Liquid Filled Capsules

    30 X 200 mg

    not in the basket chart 86949 9266

    Liquid Filled Capsules

    20 X 200 mg

    not in the basket chart 1920

    Liquid Filled Capsules

    16 X 200 mg

    not in the basket chart 86950 9275

    Related information


    Dosage

    For oral administration and short-term use only.
    Adults, the elderly and children over 12 years: The lowest effective dose should be used for the shortest duration necessary to relieve symptoms.
    The patient should consult a doctor if symptoms persist or worsen, or if the product is required for more than 10 days. Take 200mg or 400mg with water, up to three times a day as required. Leave at least four hours between doses. Do not take more than 1200 mg in any 24 hour period.


    Indications

    For the relief of mild to moderate pain such as headache, toothache, menstrual pain, backache, muscular pain, anti-inflammatory for rheumatic disease, reduction of fever. For the treatment of pain associated with migraine.


    Contra-Indications

    Patients with a known hypersensitivity to ibuprofen or any other constituent of the medicinal product. Patients who have previously shown hypersensitivity reactions (e.g. asthma, rhinitis, angioedema, or urticaria) in response to aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs). Patients with a history of, or existing gastrointestinal ulceration/perforation or bleeding, including that associated with NSAIDs. Patients with severe hepatic failure, severe renal failure or severe heart failure. Use with concomitant NSAIDs, including cyclo-oxygenase-2 specific inhibitors – increased risk of adverse reactions. During the last trimester of pregnancy as there is a risk of premature closure of the fetal ductus arteriosus with possible persistent pulmonary hypertension. The onset of labour may be delayed and the duration increased with an increased bleeding tendency in both mother and child.


    Special Precautions

    For additional information, please contact the license holder.


    Side Effects

    For additional information, please contact the license holder.


    Drug interactions

    For additional information, please contact the license holder.


    Pregnancy and Lactation

    For additional information, please contact the license holder.


    Overdose

    For additional information, please contact the license holder.


    Manufacturer
    Dexcel Ltd.
    Licence holder
    CLOSE